DR Reddys Laboratories Limited — Doxorubicin Exporter Profile
Indian Pharmaceutical Exporter · #5 for Doxorubicin · $550.0K export value · DGFT Verified
DR Reddys Laboratories Limited is the #5 Indian exporter of Doxorubicin with $550.0K in export value and 11 verified shipments. DR Reddys Laboratories Limited holds a 0.8% market share in Doxorubicin exports across 2 countries. The company exports 37 pharmaceutical products worth $62.4M across 17 therapeutic categories.
DR Reddys Laboratories Limited — Doxorubicin Export Profile: Buyers & Destinations
Where Does DR Reddys Laboratories Limited Export Doxorubicin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $500.0K | 10 | 95.2% |
| SOUTH AFRICA | $25.4K | 1 | 4.8% |
DR Reddys Laboratories Limited exports Doxorubicin to 2 countries. The largest destination is UNITED STATES accounting for 95.2% of DR Reddys Laboratories Limited's Doxorubicin shipments. These destinations reflect DR Reddys Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Doxorubicin from DR Reddys Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| DR REDDYS LABORATORIES INC | UNITED STATES | $200.0K | 4 |
| NORTHSTAR RX LLC | UNITED STATES | $150.0K | 3 |
| AMERISOURCE HEALTH SERVICES LLC | UNITED STATES | $100.0K | 2 |
| INCEPTUA INC C O J KNIPPER CO | UNITED STATES | $50.0K | 1 |
| DR REDDYS LABORATORIES PTY LIMI | SOUTH AFRICA | $25.4K | 1 |
DR Reddys Laboratories Limited supplies Doxorubicin to 5 buyers globally. The largest buyer is DR REDDYS LABORATORIES INC (UNITED STATES), followed by NORTHSTAR RX LLC (UNITED STATES) and AMERISOURCE HEALTH SERVICES LLC (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Doxorubicin Export Value and How Much Does DR Reddys Laboratories Limited Contribute?
India exported $21.8M worth of Doxorubicin through 3,492 shipments from 310 suppliers to 136 countries, serving 899 buyers globally. DR Reddys Laboratories Limited contributes $550.0K to this total, accounting for 0.8% of India's Doxorubicin exports. DR Reddys Laboratories Limited ships Doxorubicin to 2 countries through 5 buyers.
What Is the Average Shipment Value for DR Reddys Laboratories Limited's Doxorubicin Exports?
DR Reddys Laboratories Limited's average Doxorubicin shipment value is $50.0K per consignment, based on 11 shipments totaling $550.0K. The largest destination is UNITED STATES (95.2% of DR Reddys Laboratories Limited's Doxorubicin exports).
How Does DR Reddys Laboratories Limited Compare to Other Indian Doxorubicin Exporters?
DR Reddys Laboratories Limited ranks #5 among 310 Indian Doxorubicin exporters with a 0.8% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($7.5M), FRESENIUS KABI ONCOLOGY LIMITED ($3.1M), DR.REDDY'S LABORATORIES LTD ($2.5M). DR Reddys Laboratories Limited processed 11 shipments to 2 destination countries.
What Doxorubicin Formulations Does DR Reddys Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 50MG/25ML 2MG/ML SINGLE DOSE VIALS NORTHSTAR | $100.0K | 2 |
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 20MG/10ML 2MG/ML SINGLE DOSE VIALS NOVAPLUS 1000 PACKS | $50.0K | 1 |
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 20MG/10ML 2MG/ML SINGLE DOSE VIALS 3452 PACKS | $50.0K | 1 |
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 50 MG/25 ML2MG/MLSINGLE -DOSE VIALSQTY:500 NOS | $50.0K | 1 |
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 20 MG/10 ML2MG/MLSINGLE -DOSE VIALSQTY:2416 NOS | $50.0K | 1 |
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 50 MG/25 ML 2MG/ML SINGLE-DOSE VIALS NOVAPLUS 474 PACKS | $50.0K | 1 |
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 50MG/25ML 2MG/ML SINGLE DOSE VIALS 1355 PACKS | $50.0K | 1 |
| DOXORUBICIN HCL LIPOSOME INJ 50MG/25ML | $50.0K | 1 |
| DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 20MG/10ML 2MG/ML SINGLE DOSE VIALS NORTHSTAR | $50.0K | 1 |
| 300035999 DOXORUBICIN HCL LIPOSOMAL INJ.20MG/10ML | $25.4K | 1 |
DR Reddys Laboratories Limited exports 10 distinct Doxorubicin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION 50MG/25ML 2MG/M with 2 shipments worth $100.0K.
Regulatory Requirements: Exporting Doxorubicin to Key Markets
What DR Reddys Laboratories Limited must comply with to export Doxorubicin to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does DR Reddys Laboratories Limited Compare to Nearest Doxorubicin Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | VENUS REMEDIES LIMITED | $1.1M | 100 | 15 | $11.0K |
| 10 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $1.1M | 85 | 22 | $12.4K |
| 5 | DR REDDYS LABORATORIES LIMITED ★ | $550.0K | 11 | 2 | $50.0K |
| 11 | GETWELL PHARMA INDIA PRIVATE LIMITED | $525.9K | 81 | 11 | $6.5K |
| 12 | UNITED BIOTECH PRIVATE LIMITED | $508.7K | 111 | 15 | $4.6K |
DR Reddys Laboratories Limited ranks #5 among 310 Indian Doxorubicin exporters. Average shipment value of $50.0K compared to the market average of $70.4K. The closest competitors by value are VENUS REMEDIES LIMITED and NAPROD LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Doxorubicin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 639 | 18.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 577 | 16.5% |
| DELHI AIR CARGO ACC (INDEL4) | 464 | 13.3% |
| DELHI AIR | 399 | 11.4% |
| Bombay Air | 188 | 5.4% |
| AHEMDABAD AIR | 150 | 4.3% |
| AHEMDABAD AIR ACC (INAMD4) | 120 | 3.4% |
| Delhi Air | 85 | 2.4% |
Geopolitical & Trade Policy Impact on DR Reddys Laboratories Limited's Doxorubicin Exports
The global pharmaceutical export landscape has been significantly influenced by recent geopolitical events. The 2026 Strait of Hormuz crisis, initiated by military conflicts involving the United States, Israel, and Iran, led to the effective halt of shipping traffic through this critical maritime route, disrupting approximately 20% of the world's daily oil supply and causing a surge in global energy prices. (en.wikipedia.org) This disruption has had a cascading effect on shipping costs and insurance premiums, directly impacting Indian pharmaceutical exporters like Dr. Reddy's, which rely on these routes for timely delivery of products to key markets.
Simultaneously, the 2025–26 United States–India diplomatic and trade crisis, marked by the imposition of a 50% tariff on Indian exports by the U.S., has posed additional challenges. These tariffs have increased the cost of Indian pharmaceutical products in the U.S. market, potentially affecting the competitiveness of companies like Dr. Reddy's. (en.wikipedia.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. Dr. Reddy's has been proactive in adhering to these regulations, ensuring that its products meet the stringent safety and traceability standards mandated by the EU, thereby maintaining its market access and reputation.
DR Reddys Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Dr. Reddy's has demonstrated a commitment to quality by securing approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Medicines Agency (EMA). The company's recent Biologics License Application (BLA) submission for a proposed interchangeable biosimilar to Orencia® (abatacept) underscores its adherence to rigorous regulatory processes. (stockwatch.com)
However, the company has faced regulatory challenges, such as the tax audit decision from the Russian Federal Tax Service in January 2026, which reclassified certain marketing services as taxable, resulting in a penalty. (stocktitan.net) Such incidents highlight the complexities of operating in diverse regulatory environments and the importance of robust compliance frameworks.
About DR Reddys Laboratories Limited
DR Reddys Laboratories Limited exports 37 products worth $62.4M. Beyond Doxorubicin, top products include Omeprazole, Metoprolol, Diclofenac, Clopidogrel, Fexofenadine. View the complete DR Reddys Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Doxorubicin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Doxorubicin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: DR Reddys Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 11 individual customs records matching DR Reddys Laboratories Limited exporting Doxorubicin, covering 10 formulations to 2 countries via 5 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 136+ countries, 899+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Doxorubicin Export Data from DR Reddys Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddys Laboratories Limited's Doxorubicin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddys Laboratories Limited
Full Company Profile →
37 products · $62.4M total trade · 17 categories
Doxorubicin Stats
Company Overview
Top Products by DR Reddys Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for DR Reddys Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Doxorubicin. For current shipment-level data, contact TransData Nexus.